CTRI/2012/03/002486已完成3 期
A Randomized, Double-Blind Phase 3 Study Of PF-00299804, A Pan-Her Inhibitor, Vs. Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy - ARCHER 1009
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Evidence of pathologically confirmed, advanced NSCLC (with known histology).
- •2.Prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced NSCLC).
- •3.Adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.
- •4.Adequate renal, hematologic, liver function.
- •5.ECOG PS of 0-2.
- •6.Radiologically measurable disease.
排除标准
- •1.Small cell histology.
- •2.Symptomatic brain mets or known leptomeningeal mets.
- •3.Prior therapy with agent known or proposed to be active by action on EGFR tyrosine kinase or other HER family proteins.
- •4.Uncontrolled medical disorders.
研究者
相似试验
进行中（未招募）
3 期
A Study of PF-05280014 [Trastuzumab-Pfizer] or Herceptin® [Trastuzumab-EU] Plus Paclitaxel in HER2 Positive First Line Metastatic Breast Cancer TreatmentCTRI/2014/07/004786Pfizer Limited
进行中（未招募）
1 期
DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCERMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2013-001352-34-PTPfizer Inc,702
进行中（未招募）
1 期
DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCERMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864Metastatic Breast CancerEUCTR2013-001352-34-CZPfizer Inc,702
已完成
不适用
A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER-C50 Malignant neoplasm of breastMalignant neoplasm of breastC50PER-010-14PFIZER S.A.,8
进行中（未招募）
1 期
DOUBLE-BLIND STUDY OF PF-05280014 PLUS PACLITAXEL VERSUS TRASTUZUMAB PLUS PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCERMetastatic Breast CancerEUCTR2013-001352-34-HUPfizer Inc,702